Levofloxacin Prophylaxis May Reduce Infection Rate in Relapsed/Refractory AML

Share this content:
Levofloxacin Prophylaxis May Reduce Infection Rate in Relapsed/Refractory AML
Levofloxacin Prophylaxis May Reduce Infection Rate in Relapsed/Refractory AML

Antibacterial prophylaxis with levofloxacin reduced the rate of infections overall in adult patients with relapsed/refractory acute myeloid leukemia (AML) without increasing the rates of multidrug-resistant organisms, a study published in the journal Supportive Care in Cancer has shown.1

For the retrospective, single-center, cohort study, researchers enrolled 145 patients with relapsed/refractory AML admitted for reinduction chemotherapy. Of those, 48 received levofloxacin prophylaxis at a dose of 500 mg orally once daily on day 1 of chemotherapy and 97 received no prophylaxis. Levofloxacin was continued until neutrophil recovery or hospital discharge.

Of note, patients receiving broad spectrum antibiotics on day 1 of reinduction or another prophylactic antibacterial agent were not included in the study.

Results showed that 37.5% of patients in the levofloxacin group developed bacteremia compared with 53.6% in the control group (P =.0789). Researchers found that this effect was largely due to a reduction in the rate of gram-negative bacteremia, as only 2.1% in the levofloxacin group had gram-negative bacteremia vs 21.6% in the control group (P =.001).

Investigators observed no significant differences in the incidence of neutropenic fever, incidence of multidrug resistance, length of hospitalization, or mortality between the 2 groups.

The findings ultimately suggest that the benefit of antibacterial prophylaxis in this treatment setting outweighs the risk, and therefore should be considered for patients receiving intensive chemotherapy for relapsed/refractory AML.


1. Ganti BR, Marini BL, Nagel J, Bixby D, Perissinotti AJ. Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse/refractory acute myeloid leukemia. Supp Care Cancer. 2016 Oct 14. doi: 10.1007/s00520-016-3436-3. [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs